Open Label, Non-Comparative Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma
This treatment protocol allows doctors to treat advanced kidney cancer with an investigational drug called sorafenib, BAY43-9006, which is being studied in clinical trials for kidney cancer and other kinds of cancer. This treatment protocol is not a clinical trial in which sorafenib is compared to another equal treatment. All patients in this protocol will be treated with sorafenib. In addition, data from the patients who participate in this protocol will provide additional information about the drug.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : Sorafenib (Nexavar, BAY43-9006)
Phase: Phase 3
Ages Eligible For Study:
- Patients with advanced (unresectable, recurrent or metastatic) RCC - Patients reasonably likely to benefit from treatment with sorafenib as a single agent therapy - Patients with an ECOG performance status of 0-2 - Patients who will not require other systemic anticancer therapy (except for bisphosphonates) while taking sorafenib - Patients with vascular diseases such as wet macular degeneration, vasculitis, or new peptic ulcer, may be enrolled but require close monitoring in accordance with established medical practice